Statement of Changes in Beneficial Ownership (4)
January 05 2023 - 4:13PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Clark Kenneth A |
2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc.
[
SMMT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O SUMMIT THERAPEUTICS INC., 2882 SAND HILL ROAD, SUITE 106 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/3/2023 |
(Street)
MENLO PARK, CA 94025
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | $5.0 | 1/3/2023 | | A | | 35000 | | (1) | 1/3/2033 | Common Stock | 35000.0 | (2) | 35000 | D | |
Stock Option (right to buy) | $5.0 | 1/3/2023 | | A | | 44400 | | (3) | 1/3/2033 | Common Stock | 44400.0 | $1.67 (4) | 79400 | D | |
Explanation of Responses: |
(1) | The option was granted on January 3, 2023. The shares underlying the option shall vest in four equal annual installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-employee director on each such vesting date. |
(2) | Not applicable. |
(3) | The option was issued on January 3, 2023. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-employee director on each such vesting date. |
(4) | The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $74,000. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Clark Kenneth A C/O SUMMIT THERAPEUTICS INC. 2882 SAND HILL ROAD, SUITE 106 MENLO PARK, CA 94025 | X |
|
|
|
Signatures
|
/s/ Kenneth A. Clark | | 1/5/2023 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Sep 2023 to Sep 2024